Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Endocrine 2Thoracic 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 87Colorectal Neoplasms 82Stomach Neoplasms 59Pancreatic Neoplasms 56Carcinoma, Non-Small-Cell Lung 46Melanoma 34Carcinoma, Renal Cell 29Neoplasm Metastasis 25Neoplasms 24Esophageal Neoplasms 24Colonic Neoplasms 22Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Transitional Cell 20Liver Neoplasms 19Ovarian Neoplasms 17Adenocarcinoma Of Esophagus 17Esophageal Squamous Cell Carcinoma 16Triple Negative Breast Neoplasms 15Rectal Neoplasms 15Breast Neoplasms 14Biliary Tract Neoplasms 14Uterine Cervical Neoplasms 13Lung Neoplasms 12Cholangiocarcinoma 12Carcinoma, Merkel Cell 12Head and Neck Neoplasms 10Prostatic Neoplasms 9Gastrointestinal Neoplasms 9Small Cell Lung Carcinoma 8Endometrial Neoplasms 8

Interventions

selpercatinib 3Trastuzumab 2Radiotherapy 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1trametinib 1tovorafenib 1tipifarnib 1sargramostim 1pralsetinib 1mercaptoundecahydrododecaborate 1entrectinib 1dabrafenib 1cobimetinib 1alectinib 1aldesleukin 1Vemurafenib 1Taxes 1Tamoxifen 1Ritonavir 1Paclitaxel 1Nivolumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Famotidine 1Doxorubicin 1Cisplatin 1Bortezomib 14-boronophenylalanine-fructose 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Cancer, Papillary × Nivolumab × Gastrointestinal × Clear all
NCT04731467 2024-12-27

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Purple Biotech Ltd.

Phase 1/2 Completed
79 enrolled
DermatologicEndocrineGastrointestinalGynecologicHead & NeckThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡